Expert Interview
Discussing the VISION-2 phase 3 study of Microline as a potential on-demand treatment for presbyopia
Ticker(s): EYENInstitution: Kaiser Permanente
- Optometrist at Kaiser Permanente (California)
- Treats 30 patients/week with presbyopia (80% of her patients have this condition).
- Familiar with the VISION-2 phase 3 study of Microline.
How many patients do you see monthly with presbyopia?
Added By: c_adminWhat are your thoughts on the data from the VISION-2 study?
Added By: c_adminWhat exactly does the Optejet do to justify an expense greater than eyedroppers?
Added By: userad5df6c5What do you believe is the real unmet need here that this specific drug/device combo resolves?
Added By: userad5df6c5Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
